Bevacizumab May Be Next Standard of Care for Mesothelioma
Discussions About Mesothelioma at ASCO Meeting
There were other abstracts involving mesothelioma presented at the ASCO, adding even more optimism about potential treatment advances.
Dr. Raffit Hassan, mesothelioma specialist from the National Cancer Institute, detailed results of a phase I trial involving immunotherapy drug CRS-207 in combination with standard chemotherapy.
Disease control was obtained in 30 of the 32 trial participants. There was partial response in 19 patients and stable disease in 11. CRS-207 is given by
vaccination. Median duration of response was 5 months and median progression-free survival was 7.4 months.
Dr. Diego Cortinovis, San Gerardo Hospital in Monza, Italy, reported impressive results for the anti-tumor drug trabectedin in a phase II study involving
second-line treatment for sarcomatoid/biphasic mesothelioma. Trabectedin has been used effectively in soft-tissue sarcomas and for relapsed ovarian
cancers.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news
More News: Alimta | Asbestosis | Avastin | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Conferences | Environmental Health | Health | Health Insurance | Health Management | Hospital Management | Hospitals | Hypertension | Immunotherapy | Insurance | Lung Cancer | Mesothelioma | Nutrition | Ovarian Cancer | Ovaries | Sarcomas | Soft Tissue Sarcoma | Study | Toxicology | Vaccines